In 19 months routine use or the Amerlite TSH Kit. in conjunction with total T 4 • total T~and T~uptake tests. we identified 10 patients out of a total 1O.80() «)'(J9%) in whom the results wcre not only inconsistent with clinical and other biochemical assessment, but also considcrably higher than an IRMA-TSH (MAIAclone. Serono Diagnostics Ltd. eight patients; Sucrosep Boots-Celltech Diagnostic Ltd., two patients) as shown in Table 3 .
Serum samples from these patients were reassayed using an Amerlite Kit containing added mouse serum (Lot 74). All samples showed a reduction in TSH value varying from 54-91% of the original value. However, only four samples (D. F. H and I) were corrected into the appropriate clinical range and of these. three were still higher than the IRMA-TSH. A second reformulated kit containing additional 'corrective' protein (Lot 79B) showed a further reduction of interference and 9 out of 10 patients were corrected into the appropriate clinical range. Patient J. clinically thyrotoxic. still had an inappropriately normal TSH level of Amerlite. Dilution experiments (I: 1 and 1:3 with zero standard) in three patients with sufficient remaining serum. D. E and J, gave corrected Amerlite (79B) results of ()·14. ()·32 and «).()4 mUlL, respectively, which were in closer agreement with the IRMA-TSH results (0,13. ()·II and <()·I mUlL. respectively).
We conclude that the reformulation of the Amerlite Kit has reduced the likelihood of inappropriate grossly elevated results. but that interference is still present in some samples and that this will he particularly important at the hyper/euthyroid border. As we stressed previously.~it is important that clinical possibilities and suspicions be indicated on request forms and that irreversible treatment should not be applied on the basis of an abnormal TSH value alone. 
